Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Experimental Hematology & Oncology
Published in: Experimental Hematology & Oncology 1/2015

Open Access 01-12-2015 | Case report

Acute lymphoblastic leukemia with e1a3 BCR/ABL fusion protein. A report of two cases

Authors: Bernardo López-Andrade, Francesca Sartori, Antonio Gutiérrez, Lucia García, Vanesa Cunill, María Antonia Durán, Antonia Sampol, Marta Bernués, Julio Iglesias, Rafael Ramos, Josep Lladó, María Sánchez, Juan Carlos Amat, Jordi Martínez-Serra

Published in: Experimental Hematology & Oncology | Issue 1/2015

Login to get access

Abstract

B Acute Lymphoblastic leukemia (B-ALL) with Philadelphia chromosome (Ph′) is a neoplasm of lymphoblast committed to the B cell lineage. The clinical presentation of B-ALL Ph′+ is similar to B-ALL, but is more common in adults than in children. The e1a3 rare variant is produced by the fusion of BCR exon 1 to ABL exon 3. The presence of this translocation has been associated with good disease outcome for chronic myeloid leukemia in a very small series of only 5 cases; there is no such evidence for B-ALL. We report two new cases of B-ALL Ph+ with the rare e1a3 fusion transcript. The e1a3 and e1a2 (p190) transcripts have been reported to have a similar molecular weight and probably a similar clinical profile, thus in these cases the presence of e1a3 was associated with extramedullary infiltration and disease acceleration.
Literature
1.
2.
Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960;25:85–109.PubMed
3.
4.
5.
Deininger MWN, Goldman JM, Melo JV, Dc W, Deininger MWN, Goldman JM, et al. The molecular biology of chronic myeloid leukemia. Blood. 2013;96(10):3343–56.
6.
Laurent E, Talpaz M, Kantarjian H, Kurzrock R. The BCR gene and Philadelphia chromosome-positive leukemogenesis. Cancer Res. 2001;61(6):2343–55.PubMed
7.
Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph′ translocation. Nature. 1985;315(June):758–61.CrossRefPubMed
8.
Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood. 1996;88(7):2410–4.PubMed
9.
Al-Ali HK, Leiblein S, Kovacs I, Hennig E, Niederwieser D, Deininger MWN. CML with an e1a3 BCR-ABL fusion: rare, benign, and a potential diagnostic pitfall. Blood. 2002;100(3):1092–3.CrossRefPubMed
10.
Roman J, Jimenez A, Barrios M, Castillejo JA, Maldonado J, Torres A. E1A3 as a unique, naturally occurring BCR-ABL transcript in an indolent case of chronic myeloid leukaemia. Br J Haematol. 2001;114(3):635–7.CrossRefPubMed
11.
12.
13.
Shin SY, Cho JH, Kim HJ, Jang JH, Lee ST, Kim SH. Two cases of acute lymphoblastic leukemia with an e1a3 BCR-ABL1 fusion transcript. Ann Lab Med. 2015;35(1):159–61.CrossRefPubMed
14.
Langabeer SE, Haslam K, Kelly J, Leahy M, Vandenberghe E. Acute lymphoblastic leukaemia with an e1a3 BCR-ABL1 fusion. Acta Haematol. 2011;126(4):214–5.CrossRefPubMed
15.
Fujisawa S, Nakamura S, Naito K, Kobayashi M, Ohnishi K. A variant transcript, e1a3, of the minor BCR-ABL fusion gene in acute lymphoblastic leukemia: case report and review of the literature. Int J Hematol. 2008;87(2):184–8.CrossRefPubMed
16.
Burmeister T, Schwartz S, Taubald A, Jost E, Lipp T, Schneller F, et al. Atypical BCR-ABL mRNA transcripts in adult acute lymphoblastic leukemia. Haematologica. 2007;92(12):1699–702.CrossRefPubMed
17.
Wilson GA, Vandenberghe EA, Pollitt RC, Rees DC, Goodeve AC, Peake IR, et al. Are aberrant BCR-ABL transcripts more common than previously thought? Br J Haematol. 2000;111(4):1109–11.CrossRefPubMed
18.
Iwata S, Mizutani S, Nakazawa S, Yata J. Heterogeneity of the breakpoint in the ABL gene in cases with BCR/ABL transcript lacking ABL exon a2. Leukemia. 1994;8(10):1696–702.PubMed
19.
20.
Metadata
Title
Acute lymphoblastic leukemia with e1a3 BCR/ABL fusion protein. A report of two cases
Authors
Bernardo López-Andrade
Francesca Sartori
Antonio Gutiérrez
Lucia García
Vanesa Cunill
María Antonia Durán
Antonia Sampol
Marta Bernués
Julio Iglesias
Rafael Ramos
Josep Lladó
María Sánchez
Juan Carlos Amat
Jordi Martínez-Serra
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Experimental Hematology & Oncology / Issue 1/2015
Electronic ISSN: 2162-3619
DOI
https://doi.org/10.1186/s40164-016-0049-y

Other articles of this Issue 1/2015

Experimental Hematology & Oncology 1/2015 Go to the issue

Rapid communication

Deregulated expression of the HSP40 family members Auxilin-1 and -2 is indicative of proteostasis imbalance and predicts patient outcome in Ph+ leukemia

Research

Ex vivo apoptotic and autophagic influence of an estradiol analogue on platelets

Review

Effectiveness of AMD3100 in treatment of leukemia and solid tumors: from original discovery to use in current clinical practice

Research

miR-199b, a novel tumor suppressor miRNA in acute myeloid leukemia with prognostic implications

Review

Long noncoding RNAs: pivotal regulators in acute myeloid leukemia

Research

Effects of molecularly targeted therapies on murine thymus: highly selective mTOR inhibitors induce reversible thymic involution
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits